Interestingly, injection of an agrin biologic (NT-1654) was able to reverse the sarcopenia-like phenotype in SARCO mice, suggesting that modulating the agrin–LRP4–MuSK pathway may be a novel therapeutic strategy in the treatment of age-related muscle wasting, neuromuscular disease and associated muscle dysfunction [20]. Here, AGRN is linked to neuromuscular disease.